세계의 배합 화학요법 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 투여 경로별, 암 유형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Compounding Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Cancer Type, By Distribution Channel, By Region and Competition, 2020-2030F
복합 화학요법 세계 시장 규모는 2024년 50억 7,000만 달러에 달했고, 2030년까지 예측 기간 동안 연평균 5.08%의 괄목할 만한 성장이 예상됩니다.
배합화학요법은 암 환자 개개인의 필요에 따라 맞춤형 화학요법 약물을 준비하는 전문적인 업무를 말합니다. 이 과정은 필요한 전문 지식, 장비, 인프라를 갖춘 조제 약국 또는 의료 시설에서 수행합니다. 화학요법 약품은 복용액, 캡슐, 외용 크림, 좌약, 정맥 투여 제제 등 다양한 제형으로 제조됩니다. 어떤 제형을 선택할 것인가는 환자의 의학적 필요, 선호도, 치료 계획의 구체적인 요구 사항에 따라 결정됩니다. 복합 화학 요법은 특히 소아 및 노년기 환자에게 유용합니다. 소아 및 노년기 환자들은 독특한 약물 복용이 필요하거나 기존의 정제나 캡슐을 삼키는 데 어려움을 겪을 수 있습니다. 복합제는 이러한 환자의 특정 요구를 충족하도록 설계될 수 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
50억 7,000만 달러 |
| 시장 규모 : 2030년 |
67억 7,000만 달러 |
| CAGR : 2025-2030년 |
5.08% |
| 급성장 부문 |
온라인 약국 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
의약품 개발의 발전
주요 시장 이슈
품질 관리 및 안전
주요 시장 동향
무균 배합에 대한 관심 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 약제 유형별(세포독성 약물, 호르몬제, 면역조절제, 표적치료제, 지지 요법 약물)
- 투여 경로별(정맥내, 경구, 피하, 근육내, 골수강내)
- 암 유형별(유방암, 폐암, 대장암, 전립선암, 백혈병, 림프종, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 배합 화학요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 PESTEL 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Pfizer Inc.
- Baxter International Inc.
- Grifols SA
- Comecer S.P.A.
- Arxium Inc.
- Dedalus Group
- B. Braun Melsungen AG
- Omnicell Technologies Inc.
- The Metrix Company
- Sterline S.R.L.
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
Global Compounding Chemotherapy Market was valued at USD 5.07 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.08% through 2030. Compounding chemotherapy refers to the specialized practice of preparing customized chemotherapy medications tailored to the individual needs of cancer patients. This process is carried out by compounding pharmacies or healthcare facilities with the necessary expertise, equipment, and infrastructure. Compounded chemotherapy medications can be prepared in various dosage forms, such as oral solutions, capsules, topical creams, suppositories, and intravenous (IV) formulations. The choice of dosage form depends on the patient's medical needs, preferences, and the specific requirements of the treatment plan. Compounding chemotherapy is particularly valuable for pediatric and geriatric patients who may have unique dosing requirements or difficulty swallowing conventional pills or capsules. Compounded formulations can be designed to meet the specific needs of these populations.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 5.07 Billion |
| Market Size 2030 | USD 6.77 Billion |
| CAGR 2025-2030 | 5.08% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Key Market Drivers
Advancements in Drug Development
Targeted therapies have revolutionized cancer treatment by specifically targeting molecules or pathways involved in cancer growth. These therapies are designed to be more selective in attacking cancer cells while sparing healthy ones. Compounded chemotherapy drugs now include a range of targeted agents tailored to individual patient profiles. Immunotherapy drugs, such as immune checkpoint inhibitors, have emerged as a promising approach to cancer treatment. These drugs harness the patient's immune system to recognize and attack cancer cells. Compounding pharmacies prepare these immunotherapies for administration, contributing to their widespread use. The development and approval of biosimilar versions of some chemotherapy agents have increased access to these treatments while reducing costs. Compounding pharmacies may be involved in preparing and supplying biosimilars, ensuring their availability. Nanoparticle-based chemotherapy formulations have been developed to improve drug delivery and enhance the therapeutic index of chemotherapy agents. These nanocarriers can target cancer cells more precisely and reduce side effects. Compounding pharmacies are involved in preparing these advanced formulations. Liposomal encapsulation is a drug delivery technique that involves enclosing chemotherapy drugs in liposomes (tiny fat bubbles). This approach improves drug solubility, extends drug circulation in the body, and enhances drug delivery to tumor sites. Compounded liposomal chemotherapy formulations are increasingly used. Ongoing research efforts continue to identify new chemotherapy agents, combination therapies, and treatment regimens. Compounding pharmacies play a pivotal role in preparing and supplying these innovative drugs for clinical use and research purposes.
Key Market Challenges
Quality Control and Safety
Compounded medications, including chemotherapy drugs, must adhere to strict regulatory guidelines and standards set by government agencies like the U.S. Food and Drug Administration (FDA) in the United States. Compliance with these regulations is critical to ensure the safety and efficacy of compounded drugs. Maintaining consistent quality in compounded chemotherapy drugs is challenging due to variations in raw materials, compounding processes, and equipment. Quality control measures must be in place to ensure that each batch of compounded medication meets established standards. Chemotherapy drugs are typically administered intravenously, which necessitates strict sterility measures during compounding. Contamination can lead to severe infections and adverse patient outcomes. Maintaining sterility is a constant concern. Cross-contamination is a risk when multiple chemotherapy drugs are compounded in the same facility. Stringent cleaning and sanitation procedures are essential to prevent unintended mixing of drugs and contamination. Precise dosing is critical in chemotherapy to achieve the desired therapeutic effect while minimizing side effects. Variability in dosing can lead to treatment failures or toxicity. Ensuring the accuracy of compounded doses is challenging but essential. Some chemotherapy drugs are chemically unstable and can degrade over time. Compounding pharmacies must monitor and manage drug stability to ensure that patients receive medications with the intended potency and efficacy.
Key Market Trends
Rising Interest in Sterile Compounding
Sterile compounding is essential for chemotherapy drugs, which are often administered intravenously or directly into the bloodstream. Ensuring sterility prevents the risk of infections and other complications, which can be life-threatening for cancer patients with compromised immune systems. Many chemotherapy drugs are potent and require precise dosing and administration. Sterile compounding allows for the accurate preparation of these drugs to minimize the risk of dosage errors. Sterile compounding facilitates the customization of chemotherapy regimens based on individual patient profiles, including cancer type, stage, and medical history. This personalized approach aligns with the trend toward precision medicine. The development of advanced drug delivery methods, such as nanoparticle-based formulations and liposomal encapsulation, has increased the demand for sterile compounding. These delivery systems require aseptic preparation. The focus on patient-centered care in oncology emphasizes providing treatments that are safe, effective, and tailored to individual patient needs. Sterile compounding supports this approach by ensuring the highest standards of safety and quality.
Key Market Players
- Pfizer Inc.
- Baxter International Inc.
- Grifols SA
- Comecer S.P.A.
- Arxium Inc.
- Dedalus Group
- B. Braun Melsungen AG
- Omnicell Technologies Inc.
- The Metrix Company
- Sterline S.R.L
Report Scope:
In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Compounding Chemotherapy Market, By Drug Type:
- Cytotoxic Drugs
- Hormonal Agents
- Immunomodulatory Agents
- Targeted Therapies
- Supportive Care Drugs
Compounding Chemotherapy Market, By Route of Administration:
- Intravenous
- Oral
- Subcutaneous
- Intramuscular
- Intrathecal
Compounding Chemotherapy Market, By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Leukemia
- Lymphoma
Compounding Chemotherapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Compounding Chemotherapy Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.
Available Customizations:
Global Compounding Chemotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Compounding Chemotherapy Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
- 5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
- 5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Others)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
- 5.3. Market Map
6. North America Compounding Chemotherapy Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By Cancer Type
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Compounding Chemotherapy Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Cancer Type
- 6.3.1.2.4. By Distribution Channel
- 6.3.2. Mexico Compounding Chemotherapy Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Cancer Type
- 6.3.2.2.4. By Distribution Channel
- 6.3.3. Canada Compounding Chemotherapy Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Cancer Type
- 6.3.3.2.4. By Distribution Channel
7. Europe Compounding Chemotherapy Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By Cancer Type
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Compounding Chemotherapy Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Cancer Type
- 7.3.1.2.4. By Distribution Channel
- 7.3.2. Germany Compounding Chemotherapy Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Cancer Type
- 7.3.2.2.4. By Distribution Channel
- 7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Cancer Type
- 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Compounding Chemotherapy Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Cancer Type
- 7.3.4.2.4. By Distribution Channel
- 7.3.5. Spain Compounding Chemotherapy Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Cancer Type
- 7.3.5.2.4. By Distribution Channel
8. Asia-Pacific Compounding Chemotherapy Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By Cancer Type
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Compounding Chemotherapy Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Cancer Type
- 8.3.1.2.4. By Distribution Channel
- 8.3.2. India Compounding Chemotherapy Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Cancer Type
- 8.3.2.2.4. By Distribution Channel
- 8.3.3. South Korea Compounding Chemotherapy Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Cancer Type
- 8.3.3.2.4. By Distribution Channel
- 8.3.4. Japan Compounding Chemotherapy Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Cancer Type
- 8.3.4.2.4. By Distribution Channel
- 8.3.5. Australia Compounding Chemotherapy Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Cancer Type
- 8.3.5.2.4. By Distribution Channel
9. South America Compounding Chemotherapy Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By Cancer Type
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Compounding Chemotherapy Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Cancer Type
- 9.3.1.2.4. By Distribution Channel
- 9.3.2. Argentina Compounding Chemotherapy Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Cancer Type
- 9.3.2.2.4. By Distribution Channel
- 9.3.3. Colombia Compounding Chemotherapy Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Cancer Type
- 9.3.3.2.4. By Distribution Channel
10. Middle East and Africa Compounding Chemotherapy Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By Cancer Type
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Compounding Chemotherapy Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Cancer Type
- 10.3.1.2.4. By Distribution Channel
- 10.3.2. Saudi Arabia Compounding Chemotherapy Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Cancer Type
- 10.3.2.2.4. By Distribution Channel
- 10.3.3. UAE Compounding Chemotherapy market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Cancer Type
- 10.3.3.2.4. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Pfizer Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed companies)
- 15.1.5. Recent Developments
- 15.1.6. SWOT Analysis
- 15.2. Baxter International Inc.
- 15.2.1. Business Overview
- 15.2.2. Company Snapshot
- 15.2.3. Products & Services
- 15.2.4. Financials (In case of listed companies)
- 15.2.5. Recent Developments
- 15.2.6. SWOT Analysis
- 15.3. Grifols SA
- 15.3.1. Business Overview
- 15.3.2. Company Snapshot
- 15.3.3. Products & Services
- 15.3.4. Financials (In case of listed companies)
- 15.3.5. Recent Developments
- 15.3.6. SWOT Analysis
- 15.4. Comecer S.P.A.
- 15.4.1. Business Overview
- 15.4.2. Company Snapshot
- 15.4.3. Products & Services
- 15.4.4. Financials (In case of listed companies)
- 15.4.5. Recent Developments
- 15.4.6. SWOT Analysis
- 15.5. Arxium Inc.
- 15.5.1. Business Overview
- 15.5.2. Company Snapshot
- 15.5.3. Products & Services
- 15.5.4. Financials (In case of listed companies)
- 15.5.5. Recent Developments
- 15.5.6. SWOT Analysis
- 15.6. Dedalus Group
- 15.6.1. Business Overview
- 15.6.2. Company Snapshot
- 15.6.3. Products & Services
- 15.6.4. Financials (In case of listed companies)
- 15.6.5. Recent Developments
- 15.6.6. SWOT Analysis
- 15.7. B. Braun Melsungen AG
- 15.7.1. Business Overview
- 15.7.2. Company Snapshot
- 15.7.3. Products & Services
- 15.7.4. Financials (In case of listed companies)
- 15.7.5. Recent Developments
- 15.7.6. SWOT Analysis
- 15.8. Omnicell Technologies Inc.
- 15.8.1. Business Overview
- 15.8.2. Company Snapshot
- 15.8.3. Products & Services
- 15.8.4. Financials (In case of listed companies)
- 15.8.5. Recent Developments
- 15.8.6. SWOT Analysis
- 15.9. The Metrix Company
- 15.9.1. Business Overview
- 15.9.2. Company Snapshot
- 15.9.3. Products & Services
- 15.9.4. Financials (In case of listed companies)
- 15.9.5. Recent Developments
- 15.9.6. SWOT Analysis
- 15.10.Sterline S.R.L.
- 15.10.1. Business Overview
- 15.10.2. Company Snapshot
- 15.10.3. Products & Services
- 15.10.4. Financials (In case of listed companies)
- 15.10.5. Recent Developments
- 15.10.6. SWOT Analysis
16. Strategic Recommendations
17. About Us & Disclaimer
